Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Stock Information for Eton Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.